Risk factors for sclerosis
| Risk factor . | Univariate . | Multivariate* . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Patient age Per 10 y | 1.10 (1.01–1.20) | .04 | ||
| Donor age Per 10 y | 1.07 (0.96–1.18) | .24 | ||
| Patient gender | ||||
| Male | 1.00 (reference) | |||
| Female | 1.25 (0.95–1.63) | .11 | ||
| Donor–recipient gender combination | ||||
| Male to male | 1.00 (reference) | |||
| Female to male | 0.70 (0.48–1.02) | .07 | ||
| Male to female | 0.87 (0.58–1.31) | .50 | ||
| Female to female | 1.22 (0.86–1.72) | .26 | ||
| Disease risk at transplantation | ||||
| Low | 1.00 (reference) | |||
| High | 1.11 (0.84–1.48) | .46 | ||
| Stem cell graft source | ||||
| Bone marrow | 1.00 (reference) | 1.00 (reference) | ||
| Mobilized blood cells | 2.15 (1.31–3.53) | .003 | 1.99 (1.20–3.31) | .008 |
| Umbilical cord blood | 0.57 (0.08–4.29) | .59 | 0.74 (0.10–5.63) | .77 |
| Donor relation | ||||
| Related | 1.00 (reference) | |||
| Unrelated | 0.98 (0.75–1.29) | .89 | ||
| HLA matching | ||||
| Matched | 1.00 (reference) | 1.00 (reference) | ||
| Mismatched | 0.51 (0.33–0.78) | .002 | 0.57 (0.37–0.89) | .01 |
| ABO compatibility | ||||
| Match | 1.00 (reference) | 1.00 (reference) | ||
| Minor mismatch | 1.08 (0.78–1.49) | .66 | 1.13 (0.81–1.57) | .46 |
| Major mismatch | 0.62 (0.43–0.90) | .01 | 0.65 (0.45–0.94) | .02 |
| Intensity of conditioning regimen | ||||
| High | 1.00 (reference) | |||
| Reduced | 1.26 (0.94–1.68) | .12 | ||
| TBI dose in conditioning regimen | ||||
| None | 1.00 (reference) | 1.00 (reference) | ||
| ≤450 cGy | 1.38 (1.01–1.89) | .05 | 1.27 (0.93–1.75) | .14 |
| >450 cGy | 1.40 (0.99–1.99) | .06 | 1.62 (1.14–2.31) | .008 |
| ATG in conditioning regimen | ||||
| No | 1.00 (reference) | |||
| Yes | 0.55 (0.26–1.17) | .12 | ||
| GVHD prophylaxis | ||||
| Cyclosporine + MTX/MMF | 1.00 (reference) | |||
| Tacrolimus + MTX/MMF | 1.14 (0.86–1.52) | .35 | ||
| Other | 0.71 (0.29–1.73) | .45 | ||
| Prior grade II–IV acute GVHD | ||||
| No | 1.00 (reference) | |||
| Yes | 0.87 (0.65–1.17) | .37 | ||
| Prior stage 3–4 skin acute GVHD | ||||
| No | 1.00 (reference) | |||
| Yes | 1.02 (0.77–1.35) | .88 | ||
| Risk factor . | Univariate . | Multivariate* . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Patient age Per 10 y | 1.10 (1.01–1.20) | .04 | ||
| Donor age Per 10 y | 1.07 (0.96–1.18) | .24 | ||
| Patient gender | ||||
| Male | 1.00 (reference) | |||
| Female | 1.25 (0.95–1.63) | .11 | ||
| Donor–recipient gender combination | ||||
| Male to male | 1.00 (reference) | |||
| Female to male | 0.70 (0.48–1.02) | .07 | ||
| Male to female | 0.87 (0.58–1.31) | .50 | ||
| Female to female | 1.22 (0.86–1.72) | .26 | ||
| Disease risk at transplantation | ||||
| Low | 1.00 (reference) | |||
| High | 1.11 (0.84–1.48) | .46 | ||
| Stem cell graft source | ||||
| Bone marrow | 1.00 (reference) | 1.00 (reference) | ||
| Mobilized blood cells | 2.15 (1.31–3.53) | .003 | 1.99 (1.20–3.31) | .008 |
| Umbilical cord blood | 0.57 (0.08–4.29) | .59 | 0.74 (0.10–5.63) | .77 |
| Donor relation | ||||
| Related | 1.00 (reference) | |||
| Unrelated | 0.98 (0.75–1.29) | .89 | ||
| HLA matching | ||||
| Matched | 1.00 (reference) | 1.00 (reference) | ||
| Mismatched | 0.51 (0.33–0.78) | .002 | 0.57 (0.37–0.89) | .01 |
| ABO compatibility | ||||
| Match | 1.00 (reference) | 1.00 (reference) | ||
| Minor mismatch | 1.08 (0.78–1.49) | .66 | 1.13 (0.81–1.57) | .46 |
| Major mismatch | 0.62 (0.43–0.90) | .01 | 0.65 (0.45–0.94) | .02 |
| Intensity of conditioning regimen | ||||
| High | 1.00 (reference) | |||
| Reduced | 1.26 (0.94–1.68) | .12 | ||
| TBI dose in conditioning regimen | ||||
| None | 1.00 (reference) | 1.00 (reference) | ||
| ≤450 cGy | 1.38 (1.01–1.89) | .05 | 1.27 (0.93–1.75) | .14 |
| >450 cGy | 1.40 (0.99–1.99) | .06 | 1.62 (1.14–2.31) | .008 |
| ATG in conditioning regimen | ||||
| No | 1.00 (reference) | |||
| Yes | 0.55 (0.26–1.17) | .12 | ||
| GVHD prophylaxis | ||||
| Cyclosporine + MTX/MMF | 1.00 (reference) | |||
| Tacrolimus + MTX/MMF | 1.14 (0.86–1.52) | .35 | ||
| Other | 0.71 (0.29–1.73) | .45 | ||
| Prior grade II–IV acute GVHD | ||||
| No | 1.00 (reference) | |||
| Yes | 0.87 (0.65–1.17) | .37 | ||
| Prior stage 3–4 skin acute GVHD | ||||
| No | 1.00 (reference) | |||
| Yes | 1.02 (0.77–1.35) | .88 | ||
ATG, antithymocyte globulin; MTX, methotrexate; MMF, mycophenolate mofetil.
Multivariate analysis includes risk factors with at least 1 category statistically significant at P = .05 level, 977 patients included.